Tuesday, October 4, 2022


Biotechnology News Magazine

Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of haemodialysis, to the clinic.

Invizius notes the funds will be used towards H-Guard’s First-in-Man safety study commencing in 2022.

There are currently 3.3 million haemodialysis patients worldwide who receive treatment multiple times a week. Dialysis treatment can reduce life expectancy by two thirds and almost half of patients die from cardiovascular complications, in part caused by the immune system reacting to components of the dialysis apparatus.

The H-Guard® Priming Solution comprises a novel protein that lines the inside of the dialysis filter and helps dialysis to take place undetected by the body’s immune system. This suppresses the blood’s foreign body response preventing a repetitive, hostile inflammatory reaction that increases the risk of cardiovascular complications.

Richard Boyd, Chief Executive Officer of Invizius, said: “We are delighted to have been awarded this grant by the Biomedical Catalyst to bring our potentially lifesaving treatment to the clinic to improve outcomes and the quality of life of haemodialysis patients. Being one of the 17 award recipients selected out of 302 applicants is an honour and validates the potential of our cutting edge technology to solve a huge unmet need for haemodialysis patients. We are initially targeting patients with high innate immune response to dialysis, where the worldwide market for H-Guard is estimated to be worth over £1.5 billion.”

Invizius is supported by a strong syndicate of investors including Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures, Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Company has established the regulatory pathway for H-Guard® in North America and the potential for coincident approval in Europe.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine